On Tuesday, Neurocrine Biosciences, Inc (NASDAQ: NBIX) opened lower -3.25% from the last session, before settling in for the closing price of $110.60. Price fluctuations for NBIX have ranged from $105.18 to $157.98 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has jumped its sales by 24.80% annually for the last half of the decade. Company’s average yearly earnings per share was noted 24.66% at the time writing. With a float of $96.79 million, this company’s outstanding shares have now reached $99.40 million.
In an organization with 1800 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 98.06%, operating margin of 24.58%, and the pretax margin is 20.63%.
Neurocrine Biosciences, Inc (NBIX) Insider Updates
A key investor’s attitude towards the stock of the Drug Manufacturers – Specialty & Generic industry is another important factor to consider. The insider ownership of Neurocrine Biosciences, Inc is 2.92%, while institutional ownership is 94.14%. The most recent insider transaction that took place on Feb 13 ’25, was worth 181,129. In this transaction Chief Human Resources Officer of this company sold 1,551 shares at a rate of $116.78, taking the stock ownership to the 19,544 shares. Before that another transaction happened on Feb 13 ’25, when Company’s Director sold 5,844 for $116.69, making the entire transaction worth $681,914. This insider now owns 521,618 shares in total.
Neurocrine Biosciences, Inc (NBIX) Performance Highlights and Predictions
Wall Street market experts anticipate that the next fiscal year will bring earnings of 1.53 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 24.66% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 38.09% during the next five years compared to 53.47% growth over the previous five years of trading.
Neurocrine Biosciences, Inc (NASDAQ: NBIX) Trading Performance Indicators
Check out the current performance indicators for Neurocrine Biosciences, Inc (NBIX). In the past quarter, the stock posted a quick ratio of 3.28. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 4.53. Likewise, its price to free cash flow for the trailing twelve months is 19.15.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is 3.29, a number that is poised to hit 0.77 in the next quarter and is forecasted to reach 6.17 in one year’s time.
Technical Analysis of Neurocrine Biosciences, Inc (NBIX)
Let’s dig in a bit further. During the last 5-days, its volume was 1.1 million. That was inferior than the volume of 1.31 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 27.60%. Additionally, its Average True Range was 3.23.
During the past 100 days, Neurocrine Biosciences, Inc’s (NBIX) raw stochastic average was set at 3.69%, which indicates a significant decrease from 5.24% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 26.28% in the past 14 days, which was lower than the 41.44% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $123.35, while its 200-day Moving Average is $129.40. However, in the short run, Neurocrine Biosciences, Inc’s stock first resistance to watch stands at $109.76. Second resistance stands at $112.53. The third major resistance level sits at $114.16. If the price goes on to break the first support level at $105.36, it is likely to go to the next support level at $103.73. Assuming the price breaks the second support level, the third support level stands at $100.96.
Neurocrine Biosciences, Inc (NASDAQ: NBIX) Key Stats
There are currently 99,704K shares outstanding in the company with a market cap of 10.67 billion. Presently, the company’s annual sales total 2,355 M according to its annual income of 341,300 K. Last quarter, the company’s sales amounted to 627,700 K and its income totaled 103,100 K.
